Sterling Capital Management’s Compass Therapeutics CMPX Stock Holding History

Sterling Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.69K	Sell	2,585 -57	-2%	-$117	﹤0.01%	3088
2026 Q2	$5.79K	Buy	2,642 +198	+8%	+$585	﹤0.01%	2532
2026 Q1	$12.9K	Sell	2,444 -1,383	-36%	-$7.98K	﹤0.01%	2241
2025 Q4	$20.6K	Buy	3,827 +492	+15%	+$2.27K	﹤0.01%	2210
2025 Q3	$11.7K	Buy	3,335 +2,060	+162%	+$6.51K	﹤0.01%	2408
2025 Q2	$3.32K	Sell	1,275 -485	-28%	-$1K	﹤0.01%	2733
2025 Q1	$3.34K	Sell	1,760 -1,704	-49%	-$4.53K	﹤0.01%	2361
2024 Q4	$5.02K	Buy	3,464 +3,140	+969%	+$5.22K	﹤0.01%	2467
2024 Q3	$596	Buy	+324	New	+$404	﹤0.01%	2787

Other funds holding CMPX

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Simplicity Wealth Summit, New Jersey $3.43B AUM 16.22% 1-Year Est. Return

Independent Financial Group San Diego, California $5.51B AUM 33.51% 1-Year Est. Return

McAdam LLC Philadelphia, Pennsylvania $2.66B AUM 14.82% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

ACT Advisors Asheville, North Carolina $308M AUM 16.31% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Sterling Capital Management's CMPX Position: Q3 2026 in Review

Sterling Capital Management reduced its Compass Therapeutics (CMPX) stake by 2.2% in Q3 2026, selling an estimated $117 and leaving 2,585 shares worth $2.69K. The position accounts for ﹤0.01% of the portfolio, ranked #3088.

Sterling Capital Management first reported a position in CMPX in Q3 2024 and has held it in 9 quarters since. The position peaked at $20.6K in Q4 2025. 15 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

Sterling Capital Management held 2,585 shares of Compass Therapeutics worth $2.69K as of Q3 2026.
Sterling Capital Management sold 57 Compass Therapeutics shares in Q3 2026, an estimated $117.
Compass Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #3088 holding.
Sterling Capital Management first reported a position in Compass Therapeutics in Q3 2024 and has held it in 9 quarters since.
Sterling Capital Management's Compass Therapeutics position peaked at $20.6K in Q4 2025.
15 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.